Volume : 7, Issue : 2, February - 2018

TO STUDY THE EFFECTS OF 0.25 MG SINGLE DOSE OF PALONOSETRON, GIVEN INTRAVENOUSLY, ON ACUTE AND DELAYED CHEMOTHERAPY INDUCED NAUSEA AND VOMITING

Dr. Snehal N. Purandare, Dr. Abhishek N. Barve

Abstract :

<p>&nbsp;</p> <p class="MsoNormal" style="text-align:justify;line-height:150%"><span style="font-size:14.0pt;line-height:150%;font-family:&quot;Times New Roman&quot;,&quot;serif&quot;">This study aimed at reporting efficacy and tolerability of palonosetron, a second generation 5-HT₃receptor antagonist in preventing acute and delayed chemotherapy induced nausea and vomiting (CINV)</span><span style="font-size:&#10;14.0pt;line-height:150%;font-family:&quot;Times New Roman&quot;,&quot;serif&quot;;color:#2A2A2A;&#10;background:white;mso-fareast-language:EN-GB">.</span><span style="font-size:&#10;14.0pt;line-height:150%;font-family:&quot;Times New Roman&quot;,&quot;serif&quot;"> </span><span style="font-size:14.0pt;line-height:150%;font-family:&quot;Times New Roman&quot;,&quot;serif&quot;;&#10;color:#2A2A2A;mso-fareast-language:EN-GB">50 adult cancer patients received single i.v. dose of palonosetron 0.25 mg, 30 min before initiation of chemotherapy. The primary end point was proportion of patients with no emetic episodes and no rescue medication within 24 hours after chemotherapy completion (acute period). Secondary end point included efficacy in preventing delayed CINV (24-48 hours post-chemotherapy).</span><span style="font-size:14.0pt;&#10;line-height:150%;font-family:&quot;Times New Roman&quot;,&quot;serif&quot;"> The study showed that only 2 out of 50 patients had vomiting within 24 hours post chemotherapy completion, and none of the patients had nausea even after 48 hours post chemotherapy. Thus proving that efficacy of palonosetron is more for delayed CINV than for acute CINV.<o:p></o:p></span></p>